196 related articles for article (PubMed ID: 18499705)
21. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
Cohen JD; Insel TR
Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
[No Abstract] [Full Text] [Related]
22. CNTRICS final task selection: social cognitive and affective neuroscience-based measures.
Carter CS; Barch DM; Gur R; Gur R; Pinkham A; Ochsner K
Schizophr Bull; 2009 Jan; 35(1):153-62. PubMed ID: 19011231
[TBL] [Abstract][Full Text] [Related]
23. Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters.
Green MF; Lee J; Ochsner KN
Schizophr Bull; 2013 Nov; 39(6):1192-200. PubMed ID: 24072811
[TBL] [Abstract][Full Text] [Related]
24. Assessing cognitive function in clinical trials of schizophrenia.
Barnett JH; Robbins TW; Leeson VC; Sahakian BJ; Joyce EM; Blackwell AD
Neurosci Biobehav Rev; 2010 Jul; 34(8):1161-77. PubMed ID: 20105440
[TBL] [Abstract][Full Text] [Related]
25. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations.
Barch DM; Mathalon DH
Biol Psychiatry; 2011 Jul; 70(1):13-8. PubMed ID: 21334602
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological treatment of cognition in schizophrenia: an idea whose method has come.
Harvey PD; Cornblatt BA
Am J Psychiatry; 2008 Feb; 165(2):163-5. PubMed ID: 18245181
[No Abstract] [Full Text] [Related]
27. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
[TBL] [Abstract][Full Text] [Related]
28. Visual perception and its impairment in schizophrenia.
Butler PD; Silverstein SM; Dakin SC
Biol Psychiatry; 2008 Jul; 64(1):40-7. PubMed ID: 18549875
[TBL] [Abstract][Full Text] [Related]
29. CNTRICS final task selection: executive control.
Barch DM; Braver TS; Carter CS; Poldrack RA; Robbins TW
Schizophr Bull; 2009 Jan; 35(1):115-35. PubMed ID: 19011235
[TBL] [Abstract][Full Text] [Related]
30. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
[TBL] [Abstract][Full Text] [Related]
31. Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development.
Carter CS; Barch DM;
Schizophr Bull; 2012 Jan; 38(1):26-33. PubMed ID: 21914642
[TBL] [Abstract][Full Text] [Related]
32. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia.
Kern RS; Green MF; Nuechterlein KH; Deng BH
Schizophr Res; 2004 Dec; 72(1):11-9. PubMed ID: 15531403
[TBL] [Abstract][Full Text] [Related]
33. Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity.
Olbert CM; Penn DL; Kern RS; Lee J; Horan WP; Reise SP; Ochsner KN; Marder SR; Green MF
Schizophr Bull; 2013 Nov; 39(6):1211-8. PubMed ID: 24072806
[TBL] [Abstract][Full Text] [Related]
34. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Keefe RS; Goldberg TE; Harvey PD; Gold JM; Poe MP; Coughenour L
Schizophr Res; 2004 Jun; 68(2-3):283-97. PubMed ID: 15099610
[TBL] [Abstract][Full Text] [Related]
35. Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.
Meyer RE; Salzman C; Youngstrom EA; Clayton PJ; Goodwin FK; Mann JJ; Alphs LD; Broich K; Goodman WK; Greden JF; Meltzer HY; Normand SL; Posner K; Shaffer D; Oquendo MA; Stanley B; Trivedi MH; Turecki G; Beasley CM; Beautrais AL; Bridge JA; Brown GK; Revicki DA; Ryan ND; Sheehan DV
J Clin Psychiatry; 2010 Aug; 71(8):e1-e21. PubMed ID: 20797373
[TBL] [Abstract][Full Text] [Related]
36. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
37. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
Bromley E
Psychiatr Serv; 2007 Apr; 58(4):475-81. PubMed ID: 17412848
[TBL] [Abstract][Full Text] [Related]
38. The MATRICS initiative: developing a consensus cognitive battery for clinical trials.
Green MF; Nuechterlein KH
Schizophr Res; 2004 Dec; 72(1):1-3. PubMed ID: 15531401
[No Abstract] [Full Text] [Related]
39. Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis.
Cuesta MJ; Peralta V; Zarzuela A
Schizophr Res; 2007 Sep; 95(1-3):39-47. PubMed ID: 17651943
[TBL] [Abstract][Full Text] [Related]
40. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
Keefe RS; Poe M; Walker TM; Kang JW; Harvey PD
Am J Psychiatry; 2006 Mar; 163(3):426-32. PubMed ID: 16513863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
